2021
Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)
Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 5960-5971. PMID: 33821344, PMCID: PMC8532250, DOI: 10.1245/s10434-021-09897-w.Peer-Reviewed Original ResearchConceptsBreast pathologic complete responsePathologic complete responseResidual breast diseaseTriple-negative breast cancerNodal pathologic complete responsePretreatment nodal statusClinical nodal statusNeoadjuvant chemotherapyNodal statusAxillary surgeryComplete responseCALGB 40601YpN0 rateAxillary nodal involvementResidual nodal diseaseProportion of patientsCareful patient selectionBreast cancer patientsNAC regimensYpN0 diseaseYpN0 statusCN0 patientsNodal diseaseNodal involvementMultivariable analysis
2020
The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation.
Laws A, Pastorello R, Choi J, Kantor O, Grossmith S, Schnitt S, Golshan M, Mittendorf E, King T. The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation. Journal Of Clinical Oncology 2020, 38: 581-581. DOI: 10.1200/jco.2020.38.15_suppl.581.Peer-Reviewed Original ResearchPathologic complete responseResidual invasive diseaseLocal recurrenceNeoadjuvant chemotherapyBreast-conserving surgeryResidual DCISTumor responseResidual diseaseInvasive diseaseBreast pathologic complete responseDetailed pathology reviewAdjuvant endocrine therapyPoor prognostic factorModern systemic therapyTreatment effectsNeoadjuvant trastuzumabRCB scoreEndocrine therapyFree survivalMulticentric diseaseBreast conservationComplete responseLymphovascular invasionMargin statusPrognostic factors